Physician profile
Rajul Parikh
NPI 1417098930
$9,128.59
in general payments reported to CMS, 2019-2025
51 companies · $2,860 in 2025
The $2,860 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $300 · 2021: $232 · 2022: $413 · 2023: $1,752 · 2024: $2,731 · 2025: $2,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,228 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,227.84 |
| Education | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $822.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $755.99 | 2019-2025 | |
| Eisai INC. | $670.23 | 2019-2025 | |
| Lilly USA, LLC | $611.43 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $520.22 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Ucb, INC. | $477.63 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $464.17 | 2019-2025 | Ultomiris |
| Pfizer INC. | $414.64 | 2023-2025 | |
| Lundbeck LLC | $374.69 | 2023-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $369.78 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $348.40 | 2022-2025 | Crexont, Ongentys, Rytary |
| Amgen INC. | $315.12 | 2019-2025 | Uplizna |
| Biogen, INC. | $263.60 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Sk Life Science, INC. | $252.94 | 2023-2025 | |
| Emd Serono, INC. | $157.23 | 2019-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajul Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.